{"entity":{"id":"nct06493552","kind":"trial","name":"Modular Trial of sEphB4-HSA in EphrinB2-High Solid Tumors","aka":[],"tldr":"A phase 2/3 trial of Pembrolizumab, Gemcitabine, Cisplatin and Enfortumab vedotin in bladder & urothelial cancer, run by Vasgene Therapeutics, Inc, now recruiting.","summary":"Modular Trial of sEphB4-HSA in EphrinB2-High Solid Tumors is a phase 2/3 interventional study registered as NCT06493552 by Vasgene Therapeutics, Inc, with 700 participants planned, started 2025-03-15 and due to reach its primary completion in 2029-09. Interventions recorded: SEphB4-HSA, Pembrolizumab, Gemcitabine, Cisplatin and Enfortumab vedotin.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT06493552","url":"https://clinicaltrials.gov/study/NCT06493552"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["urothelial"],"sections":[],"technologies":[],"targets":[],"drugs":["pembrolizumab","gemcitabine","cisplatin","enfortumab-vedotin"],"companies":["vasgene-therapeutics"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT06493552","phase":"2/3","setting":"A Modular, Open Label, Randomized Phase II/III Trial to Assess Efficacy of Combining sEphB4-HSA (EphrinB2 Inhibitor) With Immunotherapy Regimens in Patients With EphrinB2-High Solid Tumors","sponsor":"Vasgene Therapeutics, Inc","enrolled":700,"outcomes":[]},"route":"/trials/nct06493552/","neighbours":{"cancer":[{"id":"urothelial","kind":"cancer","name":"Bladder & urothelial cancer","route":"/cancers/urothelial/"}],"drug":[{"id":"cisplatin","kind":"drug","name":"Cisplatin","route":"/drugs/cisplatin/"},{"id":"enfortumab-vedotin","kind":"drug","name":"Enfortumab vedotin","route":"/drugs/enfortumab-vedotin/"},{"id":"gemcitabine","kind":"drug","name":"Gemcitabine","route":"/drugs/gemcitabine/"},{"id":"pembrolizumab","kind":"drug","name":"Pembrolizumab","route":"/drugs/pembrolizumab/"}],"company":[{"id":"vasgene-therapeutics","kind":"company","name":"VasGene Therapeutics","route":"/companies/vasgene-therapeutics/"}]}}